Cambridge, UK based Alchemab Therapeutics last week signed a second collaboration with Eli Lilly worth up to $415M to license its IND ready program for ALS and other neurodegenerative diseases

BiotechTV - News - Cambridge, UK based Alchemab Therapeutics last week signed a second collaboration with Eli Lilly worth up to $415M to license its IND ready program for ALS and other neurodegenerative diseases